NVIDIA launches Jetson Thor robotics computers for physical AI systems
On Monday, Leerink Partners made an adjustment to the price target on Procept BioRobotics Corp (NASDAQ:PRCT), bringing it down to $90.00 from the previous $91.00. Despite the slight decrease, the firm maintained its Outperform rating on the company’s stock. According to InvestingPro data, analysts maintain a strong bullish consensus on PRCT, with price targets ranging from $60 to $91, suggesting significant upside potential from current levels around $52.
Leerink Partners’ decision followed Procept BioRobotics’ Analyst Day at the American Urological Association (AUA) and the company’s earnings report for the first quarter of 2025. The firm expressed a positive outlook on Procept’s potential in the prostate cancer space for the year ahead. Procept BioRobotics saw a revenue beat in the first quarter, surpassing expectations with approximately a 6% overall increase, including a 3% beat in the United States and a significant 29% beat internationally. InvestingPro data reveals impressive revenue growth of 59.36% over the last twelve months, with a strong gross profit margin of 62.71%.
The unchanged guidance for 2025, which includes the distribution of 52,500 handpieces and a modest upward revenue revision, is seen as conservative by Leerink Partners. This caution is consistent with the company’s historical approach to forecasts. Additionally, data from the PRCT-001 and PRCT-002 studies presented at the AUA showed promising initial efficacy for Aquablation therapy, which is anticipated to gain positive reception from physicians. Key opinion leaders (KOLs) have even suggested that Aquablation could be considered as a standard of care for benign prostatic hyperplasia (BPH). The company maintains a solid financial position with a current ratio of 8.95 and more cash than debt on its balance sheet, according to InvestingPro analysis.
Leerink Partners highlighted the favorable risk/reward scenario for Procept BioRobotics, citing the company’s valuation compared to its growth potential and the presence of near-to-intermediate term catalysts. These include commercial momentum from the ongoing HYDROS product cycle and regulatory developments that could further clarify the company’s opportunity in prostate cancer treatment. The firm reiterated its Outperform rating, signaling confidence in Procept BioRobotics’ future performance. With a market capitalization of $2.88 billion and projected revenue growth of 44% for fiscal year 2025, investors seeking deeper insights can access comprehensive analysis and additional metrics through InvestingPro’s detailed research reports.
In other recent news, Procept Biorobotics Corp reported its first-quarter 2025 earnings, exceeding analysts’ expectations. The company posted earnings per share (EPS) of -$0.45, outperforming the forecasted -$0.4907. Revenue for the quarter reached $69.2 million, surpassing the anticipated $65.43 million, marking a significant 55% year-over-year growth. Procept Biorobotics also reported an improved gross margin of 63.9%, up by 7.5 percentage points from the previous year. Furthermore, the company plans to expand its international presence, focusing on markets in the UK and Japan. Analysts from firms like Piper Sandler and Bank of America Securities have shown interest in the company’s recent performance, noting strong handpiece sales and the potential for increased utilization rates. The company has set a full-year revenue guidance of $323 million, reflecting a 44% increase year-over-year, and aims to sell 210 new robotic systems in 2025. Despite potential tariff impacts, Procept Biorobotics maintains its adjusted EBITDA loss guidance of $35 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.